AlphaNet has reached the $25 million level in donations to the Alpha-1 Foundation, according to AlphaNet CEO Robert C. Barrett. Barrett announced the milestone to his Board at their February meeting.

Since its inception in 1995, the Alpha-1 Foundation has derived nearly 50 percent of its gross revenues from AlphaNet, according to John W. Walsh, Founder and CEO of the Alpha-1 Foundation.

“The Alpha-1 community is incredibly grateful to AlphaNet for their significant contributions to the Foundation, which positively impact the life of every Alpha,” said Walsh. “The Foundation has supported Alpha-1 research and programs in nearly 70 institutions in North America and Europe. I know my co-founders, Sandy Lindsey and Susan Stanley, would be very proud to see our vision evolve so successfully.”

AlphaNet is a not-for-profit specialty disease management organization that makes available a wide range of customized patient care, education and integrated support services to Alpha-1 patients and their medical care providers. The AlphaNet Patient Service Coordinators play a vital role assisting Alphas and helping them manage their disorder. The firm also initiates research and works in support of pharmaceutical-sponsored clinical trials to aid Alphas. “Our Coordinator team embodies the founding spirit of ‘Alphas Serving Alphas’,” said Terry L. Young, AlphaNet General Manager. “As fellow Alphas they offer an extraordinarily high level of personalized service and professional interaction. No one describes the relationship better than the patients themselves, who often refer to their Coordinator as their ‘lifeline’.”

Also founded in 1995, AlphaNet has consistently supported the Alpha-1 Foundation with funding for important research efforts, as well as specialized programs benefiting the Alpha community. AlphaNet serves thousands of clients in the United States, Puerto Rico and the U.S. Virgin Islands with 25 Patient Service Coordinators. Over 75 percent of AlphaNet’s employees, and eight of the 11 members of the Board of Directors, are Alphas.

“Through cautious management, tight fiscal controls and creative entrepreneurship, our AlphaNet team has been able to consistently dedicate our excess revenues to the Foundation,” explained Barrett.
Meet Our Board of Directors

Much like the Alpha population they serve, AlphaNet’s Board of Directors is a diverse and interesting group of men and women. Eight of the 11 members are Alphas. Board members from around the U.S. are involved in medical practice, research, IT, entrepreneurial and philanthropic ventures, with a cross-section of education and experience that is inherently valuable to the company. AlphaNet’s governing body meets regularly to lend its expertise to the AlphaNet community and plays a vital role in shaping the services that AlphaNet provides. Board members are proud to be a part of AlphaNet’s tradition of education, health management, patient advocacy and financial support for Alpha-1 research.

NEW GUIDE ENHANCES STANDARDS OF CARE FOR ALPHAS

Alphas can now track their health status and gain accurate information about health-related issues with AlphaNet’s latest disease management and prevention tool. The new publication, “Individual Health Management Plan for Alphas with Lung Disease”, was developed by the AlphaNet medical team. As part of their monthly calls, AlphaNet Coordinators will ask questions to guide Alphas through this booklet. Coordinators will use these questions to help Alphas develop, maintain and evaluate on-going health management plans.

RESEARCH CONDUCTED TO GATHER BROAD-BASED INFORMATION ON THE HEALTH OF ALPHAS

This current study includes two standardized and well-validated research questionnaires known as the SF-36 and the St. George Respiratory Questionnaire. These questionnaires are used often in COPD research to acquire general information about how Alphas perceive the quality of their lives as they live with Alpha-1. You will be receiving phone calls from AlphaNet staff (not Coordinators) to complete these initial questionnaires. They will be followed by repeat calls at six-month intervals.

Data will be supplemented with information that Coordinators gather on an on-going basis. As always, any information you share is completely confidential.

Participation in these initiatives significantly adds to the body of knowledge about Alpha-1 and leads to improvements in care and treatment for all Alphas.